Document is current
Any future updates will be listed below
-
Authors
Fischinger, Carina https://orcid.org/0009-0004-9853-8112
Popp, Florian
Reichenberger, Frank
Kneidinger, Nikolaus
Tiede, Robin
von Wulffen, Werner
Welcker, Martin
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 12 December 2025
First Online: 23 January 2026
Declarations
:
: C. Fischinger: M.B.W.-Welcker GbR. F. Popp: Boehringer Ingelheim. F. Reichenberger: Boehringer Ingelheim. N. Kneidinger: Boehringer Ingelheim. R. Tiede: BDRH Service GmbH. W. von Wulffen: Boehringer Ingelheim. M. Welcker: presentations, advisories, support: Abbvie, BMS, Boehringer, Fresenius, Galapagos, Gilead, GSK, Hexal, Janssen, Johnson & Johnson, Medac, Mylan, Novartis, Sanofi-Aventis, UCB, Viatris; grants, study support: Novartis, Boehringer, UCB declare that they have no competing interests.
: All described studies on patients were carried out with the approval of the responsible ethics committee, in accordance with national law and in accordance with the Declaration of Helsinki of 1975 (in the current, revised version). A declaration of consent has been obtained from all patients involved. Trial registration: German Register of Clinical Studies (DRKS00028871).
